fashion -WSS

fashion

author：Wikipedia 2025-10-01 12:54:44 - browse：22483

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Synthetic human embryos? Researchers say term is overblown

WSS

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Citing H5N1 threat, CDC urges peak flu monitoring this summer

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Biogen joins immunology wave with $1.15 billion acquisition of HI

Ukrainian soldiers say they owe lives to US

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

fashion

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Medical leaders decry Supreme Court decision on affirmative action

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth wins $3.3 billion takeover of Amedisys

Hollywood unions extend contract negotiations for actors

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Heart attack and stroke risk calculators need revising

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

explore

Cue Health, Covid

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Making the case for fair compensation in clinical trials

As a primary care physician, here's how I hope to partner with AI

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Liver decline slowed by off

Wikipedia

explore

entertainment

explore